Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder
Brain, Behavior, & Immunity - Health · 2023-02 · 27 · 100584
DOI: 10.1016/j.bbih.2022.100584 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, Behavior, & Immunity - Health, 2023-02. Verfasst von Katrien Skorobogatov und 16 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Initiative for Neuropsychiatric and Psychopharmacological Studies (SINAPS), University Psychiatric Hospital Campus Duffel (UPCD), Duffel, …. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondation FondaMental, Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale.
Abstract (Originalsprache)
Schizophrenia (SCZ) and bipolar disorder (BD) are associated with immunological dysfunctions that have been hypothesized to lead to clinical symptomatology in particular through kynurenine pathway abnormalities. The aim of this study was thus to investigate the impact of serum kynurenine metabolite levels on diagnosis, clinical state, symptom severity and clinical course in a large French transdiagnostic cohort of SCZ and BD patients. Four patient groups (total n = 507) were included in a cross-sectional observational study: 1) hospitalized acute bipolar patients (n = 205); 2) stable bipolar outpatients (n = 116); 3) hospitalized acute schizophrenia patients (n = 111) and 4) stable schizophrenia outpatients (n = 75), in addition to healthy controls (HC) (n = 185). The quantitative determination of serum kynurenine metabolites was performed using liquid chromatography-tandem mass spectrometry. Kynurenine levels were lower in all patients combined compared to HC while ANCOVA analyses did not reveal inter-diagnostic difference between SCZ and BD. Interestingly, hospitalized patients of both diagnostic groups combined displayed significantly lower kynurenine levels than stabilized outpatients. Psychotic symptoms were associated with lower quinaldic acid (F = 9.18, p=
Autor:innen und Institutionen
- Scientific Initiative for Neuropsychiatric and Psychopharmacological Studies (SINAPS), University Psychiatric Hospital Campus Duffel (UPCD), Duffel, Belgium.
- Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Antwerp, Belgium.
- MetaBrain Research, Chilly-Mazarin, France.
- Université Paris Est Creteil, Inserm U955, IMRB Translational Neuropsychiatry Laboratory, Creteil, France.
- AP-HP, Hôpitaux Universitaires H Mondor, DMU IMPACT, FHU ADAPT, Créteil, France.
- Fondation FondaMental, Creteil, France.
Förderung
- Fondation FondaMental
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale
- Dalian Maritime University
Zitieren
APA
Skorobogatov, K., Autier, V., Foiselle, M., Richard, J. R., Boukouaci, W., Wu, C. L., Raynal, S., Carbonne, C., Laukens, K., Meysman, P., Coppens, V., le Corvoisier, P., Barau, C., De Picker, L., Morrens, M., Tamouza, R., & Leboyer, M. (2023). Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder. Brain, Behavior, & Immunity - Health, 27, 100584. https://doi.org/10.1016/j.bbih.2022.100584
Vancouver
Skorobogatov K, Autier V, Foiselle M, Richard JR, Boukouaci W, Wu CL, et al. Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder. Brain, Behavior, & Immunity - Health. 2023;27:100584. doi:10.1016/j.bbih.2022.100584
BibTeX
@article{Skorobogatov2023,
author = {Skorobogatov, Katrien and Autier, Valérie and Foiselle, Marianne and Richard, Jean-Romain and Boukouaci, Wahid and Wu, Ching-Lien and Raynal, Sophie and Carbonne, Christel and Laukens, Kris and Meysman, Pieter and Coppens, Violette and le Corvoisier, Philippe and Barau, Caroline and De Picker, Livia and Morrens, Manuel and Tamouza, Ryad and Leboyer, Marion},
title = {Kynurenine pathway abnormalities are state-specific but not diagnosis-specific in schizophrenia and bipolar disorder},
journal = {Brain, Behavior, & Immunity - Health},
year = {2023},
volume = {27},
pages = {100584},
doi = {10.1016/j.bbih.2022.100584}
}
EUVIMED